Maravai Lifesciences Holdings Stock News

Cornerstone Investment Partners LLC decreased its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 19.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,895 shares of the companys stock after selling 1,200 shares during the period. Cornerstone Investment Partners []

Wall Street analysts expect Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) to announce earnings per share of $0.38 for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Maravai LifeSciences earnings, with the lowest EPS estimate coming in at $0.35 and the highest estimate coming in at $0.43. Maravai LifeSciences reported earnings per share []

Maravai LifeSciences Holdings, Inc. (MRVI) could be a solid addition to your portfolio given a notable revision in the company’s earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on […] The post Earnings Estimates Moving Higher for Maravai LifeSciences Holdings, Inc. (MRVI): Time to Buy? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The consensus price target hints at a 25.1% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the commercial launch of its BioXp mRNA synthesis kits with CleanCap® Reagent AG, a proprietary mRNA capping technology from TriLink BioTechnologies, part of Maravai LifeSciences (NASDAQ: MRVI). These new automation kits will allow users to generate large yields of high-quality, capped mRNA to accelerate the discovery and development of mRNA-based vaccines and therapeutics.

In the last trading session, 1.32 million shares of the Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) were traded. Most recently the companys share price was $36.49, and it changed around -$1.06 or -2.82% from the last close, which brings the market valuation of the company to $9.44B. MRVI currently trades at a discount to its 52-week Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI): Would You Buy Today? Read More »

Marshall Wace LLP trimmed its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 68.8% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 73,964 shares of the companys stock after selling 163,221 shares during the quarter. Marshall Wace LLPs holdings in Maravai LifeSciences were worth $3,087,000 as of its most recent []

Wall Street brokerages predict that Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) will post $0.38 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Maravai LifeSciences earnings, with the highest EPS estimate coming in at $0.43 and the lowest estimate coming in at $0.35. Maravai LifeSciences posted earnings of $0.13 []

Carnegie Capital Asset Management LLC purchased a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 12,580 shares of the companys stock, valued at approximately $617,000. Several other hedge funds also recently modified their []

Goldman Sachs Group Inc. raised its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 5.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 137,028 shares of the companys stock after buying an additional 6,800 shares during the quarter. Goldman Sachs []

Maravai LifeSciences (NASDAQ:MRVI) updated its FY 2021 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $1.480-$1.520 for the period, compared to the Thomson Reuters consensus estimate of $1.390. The company issued revenue guidance of $770 million-$780 million, compared to the consensus revenue estimate of $764.03 million.Maravai LifeSciences also updated its []

Related Stocks: ICLR , TMO , GLOB , HTGC , OMCL , TECH , MRVI , DOCS , MRNA , AVTR , STLD , CPRI , BRK.B , SMG , TKR , PNR , TFX , GM ,

Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) price closed lower on Monday, November 15, dropping -1.73% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

The consensus price target hints at a 40.2% upside potential for Maravai LifeSciences (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni